Doctors Transplant Kidneys with Hepatitis C, Then Cure Recipients’ Infection
Last year, Penn Medicine researchers started a clinical trial (NCT02743897) to evaluate the viability of transplanting kidneys from HCV-infected donors to uninfected patients on the kidney waitlist.
RTT MolecularDX Launches Tests to Detect Drug-resistant Hepatitis Viruses
“We are most excited about our new, first-of-its-kind, HCV DR Test for Replication Complex Inhibitors (RCI) drug resistance in the NS5a gene.”
Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis
The aim of this study was to assess the cost-effectiveness of directly acting antivirals (DAAs) in CHC elderly patients.
Hepatitis B and C patients more likely to develop Parkinson's disease
The viruses hepatitis B and C may both be associated with an increased risk of Parkinson's disease, according to a study published in the March 29, 2017, online issue of Neurology®, the medical journal of the American Academy of Neurology.
ContraVir Reports New Mechanism of Action for Hepatitis B Virus Inhibitor CRV431
New studies show that CRV431 potently blocks the interaction between hepatitis B surface antigen (HBsAg), a key HBV protein, and cyclophilin A, an important cellular protein.
Struggling with Depression and Hepatitis B? You’re Not Alone
We need to be reminded once again that hepatitis B is nothing to be ashamed of, that millions of people around the world are infected not because they did anything wrong.
Iron Overload Affects More Than the Irish, People with Hepatitis B-Related Liver Damage Need to Be Tested
The relationship between iron overload and hepatitis B has been problematic, or as researchers like to say, “not well defined.”
HCV Infection May Increase Risk of Cataracts, Study Finds
A recent study suggested a link between hepatitis C (HCV) infection and the development of cataracts.The study, “Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study,” was published in the journal PLOS One.
Four-Year Entecavir Therapy Reduces Hepatocellular Carcinoma,Cirrhotic Events and Mortality in Chronic Hepatitis B Patients
Oral antiviral therapy may reduce the disease progression of chronic hepatitis B (CHB) patients.Four-year entecavir therapy significantly reduces the risk of HCC, cirrhotic events and mortality in patients with CHB-related cirrhosis.
Updated ACIP Recommendations Nix LAIV, Expand HBV Vaccination
The final 2017 adult vaccination schedule has been issued by the Advisory Panel on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC).